Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $31.00 price objective on the stock.

Several other brokerages also recently weighed in on IMNM. Stephens lifted their target price on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Monday, November 17th. Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 price target for the company. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Guggenheim upped their price objective on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, The Goldman Sachs Group started coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $22.41 on Thursday. Immunome has a 1-year low of $5.15 and a 1-year high of $25.30. The stock has a market cap of $2.06 billion, a P/E ratio of -7.60 and a beta of 2.22. The firm has a fifty day moving average price of $19.83 and a 200 day moving average price of $14.41.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, CEO Clay B. Siegall bought 4,729 shares of the firm’s stock in a transaction on Tuesday, December 30th. The shares were bought at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the transaction, the chief executive officer owned 665,254 shares of the company’s stock, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Isaac Barchas sold 383,200 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the transaction, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This represents a 15.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders acquired 68,518 shares of company stock valued at $1,453,958. 7.69% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently modified their holdings of the company. Stoneridge Investment Partners LLC boosted its position in Immunome by 5.4% during the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after purchasing an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its stake in shares of Immunome by 6.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after buying an additional 631 shares during the last quarter. Creative Planning boosted its position in shares of Immunome by 4.0% in the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Immunome by 6.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after buying an additional 1,188 shares in the last quarter. Finally, Main Management ETF Advisors LLC grew its stake in Immunome by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after acquiring an additional 1,248 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.